Acral lesions of vitiligo: why are they resistant to photochemotherapy?

被引:52
|
作者
Esmat, S. M. [1 ]
El-Tawdy, A. M. [1 ]
Hafez, G. A. [2 ]
Zeid, O. A. [1 ]
Abdel Halim, D. M. [1 ]
Saleh, M. A. [1 ]
Leheta, T. M. [1 ]
ElMofty, M. [1 ]
机构
[1] Cairo Univ, Fac Med, Dept Dermatol, Cairo, Egypt
[2] Suez Canal Univ, Fac Med, Dept Pathol, Suez, Egypt
关键词
CELL GROWTH-FACTOR; MHC CLASS-II; MELANOCYTES; EXPRESSION; RECEPTOR; ICAM-1;
D O I
10.1111/j.1468-3083.2011.04215.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Acral lesions of vitiligo are usually resistant to conventional lines of treatment as well as surgical interventions. Objective To clarify causes underlying resistance of acral lesions to pigmentation in vitiligo by studying some of the factors associated with mechanisms of repigmentation following photochemotherapy. Methods The study included twenty patients with active vitiligo. Skin biopsies were taken from lesional and perilesional skin of areas expected to respond (trunk and proximal limb) and skin of acral areas, before and after PUVA therapy. Sections were stained with H and E, Melan-A, MHCII, CD1a, SCF and c-kit protein. Results Before treatment acral areas showed significantly lower hair follicle density, melanocyte density, Langerhans cell (LC) density, epidermal MHCII expression, lesional SCF expression and perilesional c-kit expression. Following treatment with PUVA in both non-responsive acral and repigmenting non-acral lesions identical immunohistochemical changes in the form of significant decrease in LC density, epidermal MHC-II and SCF expression were observed. Conclusion The surprisingly similar histochemical changes in response to PUVA in acral and non-acral lesions did not manifest with clinical repigmentation except in non-acral ones. Factors such as inherent lower melanocyte density, lower melanocyte stem cell reservoirs and/or lower baseline epidermal stem cell factor may be considered as possible play makers in this respect.
引用
收藏
页码:1097 / 1104
页数:8
相关论文
共 50 条
  • [1] Psoralen photochemotherapy for vitiligo
    Grimes, PE
    [J]. CLINICS IN DERMATOLOGY, 1997, 15 (06) : 921 - 926
  • [2] ORAL PHOTOCHEMOTHERAPY IN VITILIGO
    ORTONNE, JP
    SANNWALD, C
    THIVOLET, J
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 1978, 105 (6-7): : 617 - 624
  • [3] KHELLIN PHOTOCHEMOTHERAPY OF VITILIGO
    HONIGSMANN, H
    ORTEL, B
    [J]. PHOTODERMATOLOGY, 1985, 2 (04) : 193 - 194
  • [4] Photochemotherapy (PUVA) in psoriasis and vitiligo
    Shenoi, Shrutakirthi D.
    Prabhu, Smitha
    [J]. INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2014, 80 (06): : 497 - 504
  • [5] PHOTOCHEMOTHERAPY OF VITILIGO WITH ORAL PHENYLALANINE
    CORMANE, RH
    SIDDIQUI, AH
    NENGERMAN, IM
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1983, 80 (04) : 367 - 367
  • [6] Effectiveness of psoralen photochemotherapy for vitiligo
    Chuan, MT
    Tsai, YJ
    Wu, MC
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 1999, 98 (05) : 335 - 340
  • [7] Acral Leukoderma: Is It Always Vitiligo?
    Martina, Emanuela
    Diotallevi, Federico
    Campanati, Anna
    Radi, Giulia
    Offidani, Annamaria
    [J]. DERMATITIS, 2021, 32 (06) : E159 - E161
  • [8] Matrix metalloproteinase in acral and non-acral vitiligo
    Esmat, Samia
    Halim, Dalia M. Abdel
    Hegazy, Rehab A.
    Sayed, Safinaz
    Saleh, Marwah A.
    [J]. PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 2018, 34 (03) : 211 - 213
  • [9] PHOTOCHEMOTHERAPY WITH TOPICAL KHELLIN AND SUNLIGHT IN VITILIGO
    ORECCHIA, G
    PERFETTI, L
    [J]. DERMATOLOGY, 1992, 184 (02) : 120 - 123
  • [10] INEFFECTIVENESS OF TOPICAL KHELLIN IN PHOTOCHEMOTHERAPY OF VITILIGO
    PROCACCINI, EM
    RICCIO, G
    MONFRECOLA, G
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 1995, 6 (02) : 117 - 120